ArticleFrontiers in immunology2026
Association of plasma ceramide with stroke-associated pneumonia in acute ischemic stroke.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of the CALLY index for functional outcomes in acute ischemic stroke: a systematic review and exploratory quantitative synthesis.Frontiers in neurology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke-associated pneumonia (SAP) is a common and severe complication of acute ischemic stroke (AIS), yet its occurrence remains unpredictable. Post-stroke immune dysregulation and systemic inflammatory responses play a crucial role in susceptibility to SAP, highlighting the need for immune-related biomarkers. Ceramide (Cer) is kind of bioactive sphingolipids involved in inflammatory signaling and immune cell regulation, and has been implicated in infection and inflammatory diseases. This study aims to explore the association between Cer and SAP and evaluate the predictive value for SAP occurrence. Methods: This study retrospectively collected a total of 266 eligible patients with AIS and 93 healthy controls. Demographic and clinical data, as well as the concentrations of plasma C16:0-Cer, C18:0-Cer, C24:1-Cer, and C24:0-Cer, were obtained from medical records and were compared before and after propensity score matching. The least absolute shrinkage and selection operator (LASSO) regression was utilized to select variables, and risk factors were detected by multivariate analysis. The predictive values were evaluated by receiver operating characteristic curves. Results: The levels of C16:0-Cer, C18:0-Cer, C24:1-Cer, C24:0-Cer and Coronary Event Risk Test 1 (CERT1) score were higher in patients with AIS than healthy controls, in which C16:0-Cer, C18:0-Cer and CERT1 score significantly elevated in SAP patients compared with non-SAP patients. Patients with minor ischemic stroke had lower levels of C16:0-Cer, C18:0-Cer and CERT1 score with those with moderate and severe ischemic stroke. Meanwhile, levels of C16:0-Cer, C18:0-Cer and CERT1 score were positively correlated with the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) score. The A2DS2 score, C16:0-Cer, high-sensitivity C-reactive protein, and neutrophil-to-lymphocyte ratio were identified as independent risk factors for SAP. C16:0-Cer exhibited a predictive value with an area under curve of 0.725, sensitivity of 74.0%, and specificity of 61.2% for SAP. Conclusion: Plasma C16:0-Cer, C18:0-Cer, and CERT1 scores were significantly elevated in patients with AIS and SAP. Among them, C16:0-Cer served as an independent predictor for SAP in AIS patients. It demonstrated moderate predictive accuracy, suggesting its potential as a novel biomarker for early SAP risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.